<DOC>
	<DOCNO>NCT01962311</DOCNO>
	<brief_summary>This project expect answer question interest assay metabolite CSF tool early diagnosis show whether possible use marker blood urine . These study also help shed light pathophysiological original early clinical disease . While ALS appear clinical syndrome pathophysiological entity unique metabolic abnormality identify could help identify mechanism disrupt therapeutic intervention possible .</brief_summary>
	<brief_title>Evaluation Metabolomic Analysis Early Diagnosis ALS</brief_title>
	<detailed_description>A blood test would allow diagnosis 1. reduce time first sign diagnosis ALS patient therapeutic treatment earlier 2. exclude rapidly non ALS avoid unnecessary investigation anxiety infect terrible prognosis disease . It currently accept neurodegenerative disease ALS begin first clinical sign patient could benefit efficient care early . Conduct prospective study 400 patient . The secondary objective : 1. attempt improve predictive power marker assay add new parameter 2. check whether assayed molecule environment accessible ( blood , urine ) would provide equivalent diagnostic power assay CSF 3. identify metabolic pathway disrupt early could relate pathogenesis neurodegeneration .</detailed_description>
	<criteria>age 3080 Consent sign affiliation social security organism Patients treat RILUZOLE Enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Spinal Cerebrospinal Fluid</keyword>
	<keyword>Urine</keyword>
	<keyword>SERUM</keyword>
	<keyword>Diagnosis</keyword>
</DOC>